IMG-007 is under clinical development by Inmagene Biopharmaceuticals and currently in Phase II for Alopecia Areata. According to GlobalData, Phase II drugs for Alopecia Areata have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMG-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMG-007 overview

IMG-007 is under development for the treatment of atopic dermatitis and alopecia areata. The therapeutic candidate acts by targeting OX40. It is administered through intravenous and subcutaneous route. It is being developed based on QuadraTek platform

It was also under development for graft versus host disease, asthma, rheumatoid arthritis and inflammatory bowel disease.

Inmagene Biopharmaceuticals overview

Inmagene Biopharmaceuticals (Inmagene) is a clinical-stage biotechnology company that develops novel therapeutics for immunological and inflammatory diseases using the QuadraTek platform. The company’s pipeline candidates include IMG-007, IMG-008, IMG-004 and IMG-020 (izokibep) and IMG-018. Its pipeline candidates treat atopic dermatitis, alopecia areata, rheumatoid arthritis (RA), chronic spontaneous urticaria (CSU), generalized pustular psoriasis (GPP), hidradenitis suppurativa (HS), psoriatic arthritis (PsA), hidradenitis suppurativa (HS), uveitis psoriasis and ankylosing spondylitis. The company works in partnership with pharmaceutical and biotechnology companies such as Hutchmed and Affibody AB. ChiInmagene is headquartered in San Diego, California, the US.

For a complete picture of IMG-007’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.